Sustained Infectious SARS-CoV-2 Presence After Protease Inhibitor Therapy In Vitro

Overview

This study demonstrates that infectious SARS-CoV-2 can persist in permissive cell cultures following treatment with 3CL protease inhibitors such as nirmatrelvir and ensitrelvir, but not after polymerase inhibitor remdesivir treatment. The infectious virus decays slowly with a half-life of about one day, potentially explaining viral rebound observed clinically after standard 5-day protease inhibitor therapy.

Background

Nirmatrelvir, combined with ritonavir as Paxlovid, is an FDA-approved oral protease inhibitor therapy for COVID-19, primarily used in elderly and high-risk patients. Despite initial clinical improvement, approximately 20% of treated patients experience viral rebound days after completing the 5-day course. Previous hypotheses including drug resistance, reinfection, and immune failure have been excluded. Understanding the mechanism behind this rebound is critical to optimizing treatment strategies.

Data Highlights

Key Findings

• Infectious SARS-CoV-2 persists in vitro after treatment with 3CL protease inhibitors nirmatrelvir and ensitrelvir.
• The infectious virus decays slowly with an approximate half-life of one day, allowing it to potentially outlast the treatment duration.
• No infectious virus persistence was observed after treatment with the polymerase inhibitor remdesivir.
• Extending nirmatrelvir treatment beyond 8 days in vitro abolished viral rebound.
• Viral rebound occurs in about 20% of patients treated with the standard 5-day protease inhibitor regimen.
• Drug resistance, reinfection, and inadequate immune response have been ruled out as causes of viral rebound.

Clinical Implications

These findings suggest that the standard 5-day course of protease inhibitor therapy may be insufficient to fully clear infectious SARS-CoV-2, leading to viral rebound. Clinicians should consider the potential benefit of extending protease inhibitor treatment duration beyond 8 days to prevent rebound, pending clinical trials. Monitoring for viral persistence post-therapy is important to reduce transmission risk during rebound episodes.

Conclusion

The persistence of infectious SARS-CoV-2 following protease inhibitor therapy provides a plausible mechanism for viral rebound observed clinically. Extending treatment duration may be a viable strategy to prevent rebound and warrants clinical investigation.

References

1. FDA -- Paxlovid Approval and Use
2. CDC Health Advisory -- SARS-CoV-2 Rebound
3. Clinical Studies -- Viral Rebound Rates and Mechanisms